<DOC>
	<DOCNO>NCT01647971</DOCNO>
	<brief_summary>The purpose study determine whether ublituximab safe effective patient relapse refractory B-cell lymphoma previously treat rituximab .</brief_summary>
	<brief_title>Study Efficacy Safety Ublituximab Patients With Relapsed Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Relapsed Refractory Bcell Lymphoma Measurable Evaluable Disease Previously treat least one line rituximab rituximab base therapy Patients ineligible high dose combination chemotherapy + stem cell transplant ECOG Performance Status 0 , 1 2 No active chronic infection Hepatitis B C history HIV base negative serology Prior chemotherapy , investigational therapy radiotherapy within 3 week study entry Prior autologous allogeneic stem cell transplantation within 3 month study entry History severe hypersensitivity anaphylaxis prior rituximab Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , brain metastasis , psychiatric illness would limit compliance study requirement Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>